In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

How Pharma Can Navigate Ups And Downs Of Vertical Integration In US

Together, we will improve patient health and experiences while lowering costs across the continuum of care.” This quote, from Andrew Witty, CEO of US health services management company Optum, after the company sealed its acquisition of DaVita Medical Group in 2019, encapsulates the oft-declared goals of vertical integration: efficiencies, improved quality of care, reduced costs. But is this the reality?

Business Strategies Commercial

Options, Expertise And Risk Tolerance Needed For Successful Value-Based Contracts

Biohaven Pharmaceuticals developed six different value-based contracting options to support the launch of acute migraine therapy, Nurtec ODT. Despite contract complexity and lingering regulatory risk, payers are aggressively pursuing value-based contracts, leading even small biopharmas to invest in strong health economics capabilities.

Business Strategies Commercial

The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit

The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.

United Kingdom Market Access

UK Health Care Industry Must Adjust To EU Free Trade Deal

“No deal” was finally off the table for UK trade in goods with the EU after an 11th hour free trade agreement was reached. But for the UK, the decision effectively means a “hard Brexit.”

Brexit Market Access

COVID Advocacy Exchange Platform Unites Patients, Industry And Experts

Last year Bristol Myers Squibb teamed up with GRYT Health to create a virtual conference and information hub geared toward connecting patients and advocates with industry leaders, clinicians and other health experts. In 2021, the COVID Advocacy Exchange will create formal working groups to address ongoing needs identified by the Exchange’s growing number of users.

Companies Coronavirus COVID-19

The COVID-19 Economic Crisis – Fallout And Opportunities

In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.

Coronavirus COVID-19 Policy & Regulation

COVID-19 Vaccines Are Coming Soon, But Therapeutics Needed Now

Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.

Coronavirus COVID-19 Distribution

The Rise And Fall And Long-Term Rise Of Digitally Enabled Health Care

COVID-19 has accelerated the adoption of telehealth, but lasting change will only happen once digital health is institutionalized in health system work flows, says Teladoc Health’s Joe DeVivo.

Business Strategies Coronavirus COVID-19

Snapshot: October Highlights

A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.

Business Strategies Commercial

Exclusive Interview: Biopharma And A Biden Administration

A Biden administration, if elected, would protect biopharmaceutical innovation, tackle the rising costs of cancer drugs and “promote science, without politics.”

US States North America

Why Value-Based Health Care Is Here To Stay

COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.

Business Strategies Commercial

Can RFID Tags Give Generics Companies An Edge?

Fresenius Kabi’s decision to add radio frequency-identification (RFID) tags to 24 products used in hospital operating rooms will help the company’s hospital pharmacy customers reduce waste, increase efficiencies and facilitate tighter medication inventory control, executives told In Vivo. COVID-19-related revenue losses may push more hospitals to adopt automated RFID medication management systems to save time and reduce labor costs.

Commercial Generic Drugs
See All
UsernamePublicRestriction

Register